1. Primary superficial Ewing sarcoma: A unique entity? A case report including novel findings of <scp> ELF3 </scp> and <scp> TNFRSF14 </scp> copy number loss
- Author
-
Julia A. Bridge, Linda D. Murphy, David P. Douglass, Gitanjali Bajaj, Gray M. Orman, and Jerad M. Gardner
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,Histology ,Copy number loss ,Adjuvant chemotherapy ,business.industry ,Clinical course ,Soft tissue ,Dermatology ,medicine.disease ,Pathology and Forensic Medicine ,Growth velocity ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Immunohistochemistry ,Cancer gene ,Sarcoma ,business - Abstract
Primary superficial Ewing sarcoma (psES) cases are exceedingly rare, with fewer than 150 cases reported in the literature. Small case series have suggested differences between psES and Ewing sarcoma (ES) of bone or deep soft tissues: psES appears to have a more indolent course and a higher 5-year overall survival rate. PsES is more common in older adolescent females as opposed to younger males in their peak growth velocity years in bone or deep soft tissue ES. We present a case report of a 17-year-old female with a relatively static nodule on her left thigh for 4 years. Morphologic, immunohistochemical, and molecular evaluations confirmed ES. Patient underwent a gross-total resection and a shortened course of adjuvant chemotherapy without radiation. Cancer gene panel testing found three gene abnormalities (in addition to EWSR1-FLI1 fusion): CCND1 copy number gain, ELF3 copy number loss, and TNFRSF14 copy number loss. To our knowledge, this is the first published case report of psES to include genomic sequencing and the first to report ELF3 and TNFRSF14 abnormalities in ES. Larger series of psES cases with genomic profiling are needed to elucidate a possible genetic etiology for its more indolent clinical course and favorable outcomes.
- Published
- 2020